LTP ltr pharma limited

Ann: Commercial Update and Regulatory Progress, page-331

  1. 8 Posts.
    lightbulb Created with Sketch. 3
    For an alleged litigator. Sorry it's what I do. I am not trying to win a Court case here, I am talking about the worst performing share purchase that I've ever made which is immaterial but upsetting as I am normally not so reckless.

    So I'm coming here saying that I didn't understand this and stuffed up buying it, and your response is to suggest that I can't coherently explain why I think I stuffed up.

    How much of this do you hold? I feel your pain honestly, but now I want to spend time really getting under the hood of what is wrong with this stock. Maybe I will write to the board and the ASX but I am open to the idea this is not a terminally silly thing to have purchased. I just can't make that argument work at the moment.

    In terms of your defence of the IP rights, there are a few things I'd like to clarify.

    • LTP doesn't own the patent. It has a license. A license is a license to use something for a period of time. The license is a non-exclusive license so come say a date in 3 years time, someone else can start selling the same product for $1 less a bottle.

    • A patent doesn't mean that it is the only way of delivering the drug via nasal spray. It's a particular solution to a problem. When I looked at the issue around patents:

    • there seems to be plenty of evidence that Pfizzer did get this working via nasal delivery:

    https://www.cbc.ca/news/science/viagra-in-nasal-spray-1.246938

    https://pubmed.ncbi.nlm.nih.gov/11249556/

    • there are multiple ways of dealing with the issue of suspending something in fluid - the issue seems to be viscosity.

    • Pfizzer seem to have patents dating back to circa 1999 around this and as best I can tell the decision not to progress doesn't seem to be documented as a failure to maintain the drug in suspension in the fluid. This article (https://pubmed.ncbi.nlm.nih.gov/17906871/) suggests that the issue is nasal congestion - i.e. there is a vascular response to arousal and the V*iagra that causes congestion.

    Is it the case that the Spontan patent deals with the issues identified in the earlier studies and if so how? Can you give me a source to the issue being crystallisation in fluid please?

    I know Director12 and Greedy want to up this stock, and I would be assisted in understanding the above, given my current position is I can't work it out based on what I have read so far.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
28.5¢
Change
-0.010(3.39%)
Mkt cap ! $31.90M
Open High Low Value Volume
31.0¢ 31.0¢ 27.5¢ $148.7K 524.0K

Buyers (Bids)

No. Vol. Price($)
1 17856 28.5¢
 

Sellers (Offers)

Price($) Vol. No.
30.0¢ 3306 1
View Market Depth
Last trade - 16.10pm 23/06/2025 (20 minute delay) ?
LTP (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.